Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication

PHASE2CompletedINTERVENTIONAL
Enrollment

390

Participants

Timeline

Start Date

April 30, 2003

Study Completion Date

April 30, 2006

Conditions
Intermittent ClaudicationPeripheral Vascular Disease
Interventions
DRUG

NM-702 (phosphodiesterase inhibitor)

Trial Locations (17)

10003

Investigator, New York

27705

Investigator, Durham

32216

Investigator, Jacksonville

33134

Investigator, Coral Gables

33761

Investigator, Clearwater

43606

Investigator, Toledo

Investigator, San Antonio

62702

Investigator, Springfield

66204

Investigator, Shawnee Mission

70124

Investigator, New Orleans

90502

Investigator, Torrance

90822

Investigator, Long Beach

92121

Investigator, San Diego

92501

Investigator, Riverside

94121

Investigator, San Francisco

98431

Investigator, Tacoma

02886

Investigator, Warwick

Sponsors
All Listed Sponsors
lead

Nissan Chemical Industries

INDUSTRY

NCT00102050 - Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication | Biotech Hunter | Biotech Hunter